Analysts Set Illumina, Inc. (NASDAQ:ILMN) Price Target at $118.31

by · The Cerbat Gem

Illumina, Inc. (NASDAQ:ILMN – Get Free Report) has been given an average recommendation of “Hold” by the twenty-one ratings firms that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and five have given a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $122.5625.

A number of research firms have recently issued reports on ILMN. Wall Street Zen cut shares of Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, January 3rd. TD Cowen raised their price objective on shares of Illumina from $115.00 to $140.00 and gave the stock a “hold” rating in a research report on Wednesday. Guggenheim boosted their price objective on Illumina from $114.00 to $144.00 and gave the stock a “buy” rating in a report on Monday. Zacks Research downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 31st. Finally, UBS Group increased their target price on Illumina from $110.00 to $120.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st.

Read Our Latest Stock Report on Illumina

Illumina Stock Performance

Shares of NASDAQ ILMN opened at $150.14 on Monday. The company has a current ratio of 1.43, a quick ratio of 1.12 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $22.94 billion, a P/E ratio of 33.66, a P/E/G ratio of 2.46 and a beta of 1.41. Illumina has a 12 month low of $68.70 and a 12 month high of $153.06. The stock has a 50 day moving average of $128.72 and a 200-day moving average of $109.03.

Illumina (NASDAQ:ILMN – Get Free Report) last announced its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.18. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the firm posted $1.14 EPS. The company’s quarterly revenue was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, equities research analysts predict that Illumina will post 4.51 EPS for the current year.

Insider Buying and Selling at Illumina

In other Illumina news, Director Scott Gottlieb purchased 500 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The shares were acquired at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the purchase, the director owned 12,523 shares of the company’s stock, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Scott M. Davies sold 323 shares of the firm’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the transaction, the insider directly owned 17,887 shares in the company, valued at approximately $2,434,241.83. This represents a 1.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 2.60% of the stock is owned by company insiders.

Institutional Trading of Illumina

A number of institutional investors have recently bought and sold shares of the business. Board of the Pension Protection Fund bought a new position in shares of Illumina during the fourth quarter worth approximately $26,000. Rise Advisors LLC boosted its stake in shares of Illumina by 173.6% in the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after buying an additional 224 shares during the period. Parkside Financial Bank & Trust grew its position in Illumina by 65.7% during the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after buying an additional 115 shares in the last quarter. Quent Capital LLC bought a new position in Illumina during the 3rd quarter worth $29,000. Finally, Quarry LP bought a new position in Illumina during the 3rd quarter worth $32,000. Institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

(Get Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Read More